{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:23:57Z","timestamp":1788279837502,"version":"build-2803163510"},"reference-count":45,"publisher":"Impact Journals, LLC","issue":"30","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,4,20]]},"DOI":"10.18632\/oncotarget.24989","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T20:09:50Z","timestamp":1524254990000},"page":"21166-21181","source":"Crossref","is-referenced-by-count":16,"title":["Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells"],"prefix":"10.18632","volume":"9","author":[{"given":"Vineela","family":"Chukkapalli","sequence":"first","affiliation":[{"name":"Departments of Hematology, Oncology and Stem Cell Therapy, Rush University Medical Center, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Venugopal","sequence":"additional","affiliation":[{"name":"Departments of Hematology, Oncology and Stem Cell Therapy, Rush University Medical Center, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Borgia","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Cell and Molecular Medicine, Rush University Medical Center, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,4,20]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Jemal","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Gascoyne","year":"2009","journal-title":"Blood"},{"key":"3","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Melinamani","year":"2014","journal-title":"Blood"},{"key":"4","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1200\/jco.2013.52.2466","article-title":"Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network","volume":"32","author":"Hallek","year":"2014","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1200\/jco.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Canellos","year":"2009","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Scotland","year":"2014","journal-title":"Blood"},{"key":"7","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/0008-5472.CAN-08-0555","article-title":"The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation","volume":"68","author":"Andreeff","year":"2008","journal-title":"Cancer Res"},{"key":"8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1172\/JCI38942","article-title":"Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction","volume":"120","author":"Andreeff","year":"2010","journal-title":"J Clin Invest"},{"key":"9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrc2981","article-title":"Regulation of cancer cell metabolism","volume":"11","author":"Mak","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10","doi-asserted-by":"publisher","first-page":"51435","DOI":"10.18632\/oncotarget.9843","article-title":"Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport","volume":"7","author":"Andreeff","year":"2016","journal-title":"Oncotarget"},{"key":"11","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Thompson","year":"2009","journal-title":"Science"},{"key":"12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","article-title":"The biology of cancer: metabolic reprogramming fuels cell growth and proliferation","volume":"7","author":"Thompson","year":"2008","journal-title":"Cell Metab"},{"key":"13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.it.2009.02.002","article-title":"The multiple facets of mTOR in immunity","volume":"30","author":"Saemann","year":"2009","journal-title":"Trends Immunol"},{"key":"14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cmet.2012.12.001","article-title":"AMPK is a negative regulator of the Warburg effect and suppresses tumor growth","volume":"17","author":"DeBerardinis","year":"2013","journal-title":"Cell Metab"},{"key":"15","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1161\/CIRCULATIONAHA.107.744490","article-title":"Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells","volume":"117","author":"Zou","year":"2008","journal-title":"Circulation"},{"key":"16","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1172\/JCI40671","article-title":"Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1\/AMPK pathway via a decrease in hepatic energy state","volume":"120","author":"Viollet","year":"2010","journal-title":"J Clin Invest"},{"key":"17","doi-asserted-by":"publisher","first-page":"e02242","DOI":"10.7554\/eLife.02242","article-title":"Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis","volume":"3","author":"Chandel","year":"2014","journal-title":"eLife"},{"key":"18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bbrc.2015.03.178","article-title":"Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor","volume":"461","author":"Suzuki","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"19","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1038\/cddis.2012.13","article-title":"Therapeutic metformin\/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy","volume":"3","author":"Zhao","year":"2012","journal-title":"Cell Death Dis"},{"key":"20","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1158\/2159-8290.CD-12-0263","article-title":"Investigating metformin for cancer prevention and treatment: the end of the beginning","volume":"2","author":"Pollak","year":"2012","journal-title":"Cancer Discov"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Singh, Gu, Yanamadala, Czuczman, Hernandez-llizaliturri. Metformin Lowers The Mitochondrial Potential Of Lymphoma Cells and Its Use During Front-Line Rituximab-Based Chemo-Immunotherapy Improves The Clinical Outcome Of Diffuse Large B-Cell Lymphoma. Blood. 2013; 122. Abstr 1825.","DOI":"10.1182\/blood.V122.21.1825.1825"},{"key":"22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2337\/dc11-1313","article-title":"Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival","volume":"35","author":"Morgan","year":"2012","journal-title":"Diabetes Care"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Karmali, Borgia, Gordon, Venugopal, Frankenberger. Identification of a Meta-Gene Network Associated with Metformin Sensitivity and Clinical Outcomes in Double Hit and Double Expresser Lymphomas. Blood. 2015; 126. Abstr 2431.","DOI":"10.1182\/blood.V126.23.2431.2431"},{"key":"24","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ceb.2006.10.004","article-title":"How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane?","volume":"18","author":"Youle","year":"2006","journal-title":"Curr Opin Cell Biol"},{"key":"25","doi-asserted-by":"publisher","first-page":"1010428317695965","DOI":"10.1177\/1010428317695965","article-title":"B-cell lymphoma 2 inhibitor ABT-737 induces Beclin1- and reactive oxygen species-dependent autophagy in Adriamycin-resistant human hepatocellular carcinoma cells","volume":"39","author":"Zhang","year":"2017","journal-title":"Tumour Biol"},{"key":"26","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1210\/me.2005-0222","article-title":"Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis","volume":"20","author":"Fajas","year":"2006","journal-title":"Mol Endocrinol"},{"key":"27","doi-asserted-by":"publisher","first-page":"56456","DOI":"10.18632\/oncotarget.10919","article-title":"Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma","volume":"7","author":"Brodie","year":"2016","journal-title":"Oncotarget"},{"key":"28","first-page":"45","article-title":"The hyperlactatemic effect of biguanides: a comparison between phenformin and metformin during a 6-month treatment","volume":"11","author":"Lenti","year":"1989","journal-title":"Riv Eur Sci Med Farmacol"},{"key":"29","first-page":"18","article-title":"Phase I study of ABT-199 (GDC-0199) in patients with relapsed\/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses","volume":"12","author":"Dunbar","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1186\/1471-2407-12-517","article-title":"andanti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma","volume":"12","author":"Chen","year":"2012","journal-title":"BMC Cancer"},{"key":"31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3892\/ijo.2012.1722","article-title":"Antitumor effect of metformin in esophageal cancer:study","volume":"42","author":"Mori","year":"2013","journal-title":"Int J Oncol"},{"key":"32","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1158\/1535-7163.MCT-11-0594","article-title":"The antidiabetic drug metformin inhibits gastric cancer cell proliferationand","volume":"11","author":"Himoto","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"33","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3892\/etm.2015.2220","article-title":"Metformin inhibits the proliferation of A431 cells by modulating the PI3K\/Akt signaling pathway","volume":"9","author":"Ma","year":"2015","journal-title":"Exp Ther Med"},{"key":"34","first-page":"1169","article-title":"Antidiabetic drug metformin mitigates ovarian cancer SKOV3 cell growth by triggering G2\/M cell cycle arrest and inhibition of m-TOR\/PI3K\/Akt signaling pathway","volume":"21","author":"He","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"35","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1093\/carcin\/bgt307","article-title":"Metformin targets c-MYC oncogene to prevent prostate cancer","volume":"34","author":"Li","year":"2013","journal-title":"Carcinogenesis"},{"key":"36","doi-asserted-by":"publisher","first-page":"57733","DOI":"10.18632\/oncotarget.17496","article-title":"Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy; translational biology and rationale for current clinical trials","volume":"8","author":"Tsakiridis","year":"2017","journal-title":"Oncotarget"},{"key":"37","doi-asserted-by":"publisher","first-page":"e1002309","DOI":"10.1371\/journal.pbio.1002309","article-title":"Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis","volume":"13","author":"Jones","year":"2015","journal-title":"PLoS Biol"},{"key":"38","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3345\/kjp.2016.59.9.374","article-title":"Metformin displaysandantitumor effect against osteosarcoma","volume":"59","author":"Lee","year":"2016","journal-title":"Korean J Pediatr"},{"key":"39","doi-asserted-by":"publisher","first-page":"e83832","DOI":"10.1371\/journal.pone.0083832","article-title":"Metformin as an Adjuvant Drug against Pediatric Sarcomas: Hypoxia Limits Therapeutic Effects of the Drug","volume":"8","author":"Scotlandi","year":"2013","journal-title":"PLoS One"},{"key":"40","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.2337\/dc09-1284","article-title":"Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations","volume":"33","author":"Andersson","year":"2010","journal-title":"Diabetes Care"},{"key":"41","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Morris","year":"2005","journal-title":"BMJ"},{"key":"42","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.4161\/cc.26641","article-title":"Glucose promotes breast cancer aggression and reduces metformin efficacy","volume":"12","author":"Thor","year":"2013","journal-title":"Cell Cycle"},{"key":"43","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1530\/erc-15-0402","article-title":"Glucose-deprivation increases thyroid cancer cells sensitivity to metformin","volume":"22","author":"Vasko","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"44","doi-asserted-by":"publisher","first-page":"e108444","DOI":"10.1371\/journal.pone.0108444","article-title":"Mechanisms by Which Low Glucose Enhances the Cytotoxicity of Metformin to Cancer Cells Bothand","volume":"9","author":"Miskimins","year":"2014","journal-title":"PLoS One"},{"key":"45","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.exphem.2011.05.002","article-title":"Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression","volume":"39","author":"Akao","year":"2011","journal-title":"Exp Hematol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24989","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T16:37:21Z","timestamp":1589042241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,20]]},"references-count":45,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2018,4,20]]}},"alternative-id":["24989","29765528"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.24989","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,20]]}}}